Wednesday 29 April 2026 07:00 [PDT] 10:00 [EDT] 15:00 [BST] Alternative time zones Discover how Exazym®’s BOLD amplification technology delivers 180x improved sensitivity for cardiac troponin I detection via standard ELISA. Detecting ultra-low levels of cardiac troponin I (cTnI) is crucial for cardiac research, yet standard assays often fall short for demanding applications like biomarker studies or drug safety monitoring. In this webinar, Peter Stenlund from Cavidi demonstrates how BOLD (Binding Oligo Ladder Detection) signal amplification achieved a 180-fold sensitivity improvement in a human cTnI sandwich ELISA, lowering the detection limit to 0.07 pg/mL, without specialized equipment or major protocol changes. Discover how to elevate your cardiac biomarker research using existing workflows. Can’t see the form below? Register for the webinar here. [ui-tabs] [ui-tab title=”REGISTER NOW”] hbspt.forms.create({ portalId: “6893718”, formId: “bdd3097a-75f1-45bf-9028-5811beb5e56f”, region: “na1″ }); [/ui-tab] [ui-tab title=”What will you learn?”] What will you learn? Step-by-step mechanics behind BOLD signal amplification, from antibody conjugation to signal generation How to integrate BOLD into existing ELISA protocols with minimal adjustments, including optimizations for capture/detector antibodies and temperature flexibility How Exazym®’s BOLD signal amplification technology works within standard sandwich ELISA workflows to achieve a 180-fold improvement in cardiac troponin I detection sensitivity How the cTnI detection limit was lowered to 0.07 pg/mL, enabling detection of heart injury at its earliest molecular stages Real-world impact of ultra-sensitive cTnI detection: identifying cardiotoxic effects sooner in drug development, unlocking new insights into heart disease progression and improving patient care through earlier risk detection [/ui-tab]…
